BioSante Pharmaceuticals to Present at 2011 BIO CEO & Investor Conference

BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company focused on developing products for female sexual health and oncology, will present at the 13th Annual CEO & Investor Conference hosted by the Biotechnology Industry Organization (BIO). Stephen M. Simes, BioSante's president & CEO, will provide an overview of the company and an update on LibiGel[R] (testosterone gel) Phase III clinical development program, including safety data.

Key Takeaways:

• BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) will present at the 2011 BIO CEO & Investor Conference, hosted by the Biotechnology Industry Organization (BIO), on February 14-15, 2011.
• Stephen M. Simes, BioSante's president & CEO, will speak on February 14, 2011 at 3:30 pm EST, providing an overview of the company and an update on LibiGel[R] (testosterone gel) Phase III clinical development program.
• LibiGel[R] is a testosterone gel for the treatment of female sexual dysfunction (FSD), currently in Phase III clinical development under a U.S. Food and Drug Administration (FDA) Special Protocol Assessment.
• BioSante is developing a portfolio of cancer vaccines, four of which have been granted Orphan Drug designation, and are currently in several Phase II clinical trials.
• The company also has other products in development, including Bio-T-Gel™, a testosterone gel for male hypogonadism licensed to Teva Pharmaceuticals, and an oral contraceptive in Phase II clinical development using BioSante patented technology.
• The BIO CEO & Investor Conference is the largest investor conference focused on the biotechnology industry, featuring corporate presentations from over 120 companies, workshops, plenary and panel sessions, and numerous networking opportunities.

Statistics:

• The 13th Annual CEO & Investor Conference will take place on February 14-15, 2011.
• BioSante's LibiGel[R] Phase III clinical development program is currently in progress.
• BioSante is developing four cancer vaccines, four of which have been granted Orphan Drug designation.
• The company has licensed Bio-T-Gel™, a testosterone gel for male hypogonadism, to Teva Pharmaceuticals.
• Over 120 companies will present at the conference.
• The conference will feature numerous workshops, plenary and panel sessions, and networking opportunities.

Sources:

• Cancer Vaccine Week editors, "BioSante Pharmaceuticals, Inc. - 2011 BIO CEO & Investor Conference"
• NewsRx.com, "BioSante Pharmaceuticals to Present at 2011 BIO CEO & Investor Conference"
• BioSante Pharmaceuticals, Inc., "About Us" (www.biosantepharma.com)